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recurrence continues to occur beyond 5 years (7).
Furthermore, when compared with the initial results (5), the
updated results of TARGIT-A (4) demonstrate a much
higher increase in the rate of local recurrences for PBI (23
vs 6) compared with external beam radiotherapy group (11
vs 5). Further, we disagree with the authors (1) that this
short-term follow-up can be used to report and conclude
about the rates of secondary cancers (8). Finally, the
authors claimed that the experimental arm had less car-
diovascular toxicity (1), whereas the total number of pa-
tients in both groups was very low (2 vs 8), and because the
data for left-sided cancers was not separately presented in
any of the TARGIT-Aerelated publications, nor even the
times of the cardiac deaths, their analysis of cardiovascular
disease is misleading (4).
It seems that only “time” will resolve the “clash of the
titans”dhopefully not at the expense of our patients. Until
the publication of final long-term results, we recommend
restraint before implementing this technique outside of
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of 762,468 patients. Radiother Oncol 2015;114:56-65.In Regard to Vaidya et alTo the Editor: The TARGeted Intra-operative radioTherapy
(TARGIT) trial investigated the noninferiority of low-
energy 50-kV x-rays administered at surgery versus con-
ventional external beam radiation therapy (EBRT). The
authors concluded that the TARGIT treatment was non-
inferior to EBRT because a prespecified noninferiority
boundary of 2.5% absolute difference in local recurrence
was not exceeded.
This trial has several weaknesses impacting the reli-
ability of the authors’ conclusions that have been pub-
lished earlier (1, 2). We wish to highlight a few of them.
First, every center was allowed to restrict the inclusion
criteria beyond the protocol and to stipulate local policy
for EBRT. This could be a confounding element, espe-
cially considering that the protocol allowed EBRT for
patients randomized to the TARGIT arm who had unfa-
vorable features found either during surgery or subse-
quently in the pathological examination (about 14%). The
authors maintained that in these cases, intraoperative ra-
diation therapy given as a boost was to be considered
equivalent to the EBRT arm, some of whose patients did
not even receive a boost because of the center’s local
policy. If the EBRT policy varied between centers, it
would be difficult to assess the equivalence between a
50-kV x-ray intraoperative radiation therapy boost and
EBRT treatment, given the difference in boost dosages
and the different centers’ policies for EBRT.
Second, the authors of the TARGIT trial point out that the
median follow-up of patients in their study (29 months, not
5 years as reported) covers the peak hazard of local recur-
rence that they maintain occurs between 2 and 3 years after
Volume 92  Number 5  2015 Comments 961surgery (3). However, considering that the population
included was dominated by patients with small, estrogen
receptorepositive tumors, most of whom received endocrine
therapy, the peak of recurrence will occur significantly later
than 2 to 3 years (4). This is certainly the experience of every
practicing breast clinician for such low-risk women. The
TARGIT trialists’ assertion of breast cancers peaking for this
low-risk cohort of patients is simply not credible.
Moreover, these good-prognosis patients may not
need radiation therapy at all when receiving endocrine
therapy (5), even though adequate breast irradiation without
5 years of hormonal therapy will probably result in a
similar recurrence risk with a much better quality of life.
We feel that even if the TARGIT treatment is very
appealing as a time- and cost-saving technique (as are other
approaches for partial breast delivery), more maturity in
the data is needed to determine its efficacy and assert
noninferiority versus EBRT, which remains the current
standard of care.
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trial. Lancet Oncol 2015;16:266-273.In Regard to Hepel and WazerTo the Editor: I read the Red Journal’s editorial by Hepel
and Wazer (1) with interest. I agree with many issues raised
by the authors, yet the profound thoughts need further
scrutiny.
If flawed studies (based on technique, randomization,
statistics, and subgroup analyses, and others) should not be
the basis of a future standard of care, then should conclu-
sions of past trials, using what today would clearly be
considered “flawed study,” continue to be the basis of to-
day’s practice patterns? Also, if these issues (like dose,
fractionation schedules, and others) were worth studying a
few decades ago, then should they not be repeated with
modern computer-based planning and technology, along
with our current understanding of tumor biology and host-
related factors?
